New RNA drug aims to reduce blood removal in polycythemia vera patients
NCT ID NCT05499013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The drug works by blocking a protein that controls iron use, which may lower red blood cell production and reduce the need for regular blood removal (phlebotomy). The trial has two phases: first, an open-label dose-finding part, then a randomized double-blind phase where some patients get the drug and others get a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SLN124 (a small interfering RNA drug that targets a protein involved in iron regulation)
What this could lead to
If it works, this could reduce the need for frequent blood removal (phlebotomy) and help manage polycythemia vera more effectively.
What could go wrong
This is an early-phase trial with only 69 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linear Clinical Research
Nedlands, Australia
-
Research Site
Hammond, Louisiana, 70403, United States
-
Research Site
Buffalo, New York, 14203, United States
-
Research Site
New York, New York, 10029, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Huntsville, Texas, 77340, United States
-
Research Site
Benowa, Australia
-
Research Site
Hobart, Australia
-
Research Site
Kurralta Park, Australia
-
Research Site
Melbourne, Australia
-
Research Site
Richmond, Australia
-
Research Site
Plovdiv, Bulgaria
-
Research Site
Toronto, Canada
-
Research Site
Freiburg im Breisgau, Germany
-
Research Site
Hanover, Germany
-
Research Site
Alessandria, Italy
-
Research Site
Meldola, Italy
-
Research Site
Johor Bahru, Malaysia
-
Research Site
Kuala Terengganu, Malaysia
-
Research Site
Kuantan, Malaysia
-
Research Site
Kuching, Malaysia
-
Research Site
Gdansk, Poland
-
Research Site
Katowice, Poland
-
Research Site
Lublin, Poland
-
Research Site
Barcelona, Spain
-
Research Site
Madrid, Spain
-
Research Site 2
Melbourne, Australia
-
Research Site 2
Plovdiv, Bulgaria